Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Recs

1
Player Avatar jlanganki (< 20) Submitted: 12/7/2010 11:30:07 PM : Outperform Start Price: $9.63 ALNY Score: +543.92

Priced at near cash on hand, with bright prospects in the coming years.

Featured Broker Partners


Advertisement